Public health, innovation, intellectual property and trade

Research and development, innovation

Request for Proposals:
Consultancy to conduct feasibility studies of the draft WHO toolkit on antimicrobial stewardship programmes for hospitals in low- and middle-income countries (LMICs)

The purpose of the Request for Proposal (RFP) is to select a suitable contractor to carry out the following work: Overuse and misuse of antibiotics is a main driver for the global increase in antimicrobial resistance(AMR). With the implementation of National action plans on AMR, countries have expressed a need for guidance on how to optimize antibiotic use in humans. As a response the WHO in collaboration with selected experts, have developed a antimicrobial stewardship toolkit for hospitals in low-and middle income countries. This consultancy will play a key role in leading feasibility studies of the draft toolkit in low-and middle income hospital settings.

For more information including eligibility criteria and submission forms please download the Request for Proposals below.

Please note that pages 27-31 are the pages to be completed by the bidders for submission by email: iauinfo@who.int.
The remaining pages should not be changed.


Request for Proposals:
Consultancy to update the antibacterial clinical development pipeline analysis

The purpose of the Request for Proposal (RFP) is to select a suitable contractor to carry out the following work: Consultancy to support the update of the antibacterial clinical development pipeline analysis in 2018 and 2019.

For more information including eligibility criteria and submission forms please download the Request for Proposals below.

Please note that pages 27-31 are the pages to be completed by the bidders for submission by email: iauinfo@who.int.
The remaining pages should not be changed.


Member State Consultation on the Global Framework for Development and Stewardship to Combat Antimicrobial Resistance

Dates of the meeting: 9-10 November 2017
Location: Geneva, Switzerland
- Updated Framework


Our work on health research and development encompasses two main components:

  • Research & Development: Financing and Coordination
  • WHO strategy on research for health

Research & Development: Financing & Coordination

The Consultative Expert Working Group (CEWG) on Research and Development: Financing and Coordination was mandated to take forward the work of its predecessor, the Expert Working Group on R&D Financing and Coordination (EWG); deepen the analysis of the proposals in the EWG’s report; consider additional submissions and proposals from Member States, any regional and subregional consultations, and from other stakeholders; and to examine the appropriateness of different R&D financing approaches and the feasibility of implementation of these approaches in each of the six WHO regions, with subregional analysis, as appropriate.

In resolution WHA66.22 the Health Assembly requested the Director-General, inter alia to: (1) establish a global health research and development observatory within the Secretariat in order to monitor and analyse relevant information on health research and development; (2) review existing mechanisms in order to assess their suitability to perform the coordination function of health research and development; and (3) explore and evaluate existing mechanisms for financial contributions to health research and development and, if there is no suitable mechanism, to develop a proposal for effective mechanisms, and a plan to monitor their effectiveness independently.

Background Documents for the Seventieth World Health Assembly: May 2017

Provisional Agenda Item 12.2: Antimicrobial resistance

This document provides additional background information to WHA document A70/12 Global Action Plan on Antimicrobial Resistance. It describes the current state of play and the way forward with respect to the establishment of a global framework for development and stewardship to combat antimicrobial resistance. The document was developed in close collaboration with the World Organisation for Animal Health (OIE) and the Food and Agriculture Organization of the United Nations (FAO). It builds upon the options for the development of such a framework presented to the Sixty-ninth World Health Assembly.

Provisional Agenda Item 13.5: Follow-up of the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination

WHA69.23, inter alia, requested the Director-General to submit to the Seventieth World Health Assembly, through the Executive Board at its 140th session, a proposal with goals and an operational plan for a voluntary pooled fund to support research and development for Type III and Type II diseases and specific research and development needs of developing countries in relation to Type I diseases. EB140/21 (annex 2) addresses this request in general. TDR, the Special Programme for Research and Training in Tropical Diseases, has developed a more detailed draft operational plan based on input received during the 140th session of the Executive Board.

An Equal Opportunity: Achieving Access 2030

Financing the Strategic Workplan to Address Global Health Research & Development Needs

Open-ended meeting of Member States: 02-04 May 2016

WHA66.22 requests the Director-General to convene an open-ended meeting of Member States prior to the 69th World Health Assembly, in order to assess progress and continue discussions on the remaining issues in relation to monitoring, coordination and financing for health research and development.

WHO strategy on research for health

The strategy has five main Goals:

  • Capacity - building capacity to strengthen health research systems
  • Priorities - supporting the setting of research priorities that meet health needs particularly in low and middle income countries
  • Standards - creating an environment to create good research practice and enable the greater sharing of research evidence, tools and materials
  • Translation - ensuring quality evidence is turned into products and policy
  • Organization - action to strengthen the research culture within WHO and improve the management and coordination of WHO research activities

ESSENTIAL MEDICINES AND HEALTH PRODUCTS



Contacts

Public health, innovation, intellectual property and trade
phidepartment@who.int

Dr Suzanne Hill
Director, EMP
Essential Medicines and Health Products (EMP)

Dr Marie-Paule Kieny
Assistant Director-General, HIS
Health Systems and Innovation (HIS)